# Neovascular Age-Related Macular Degeneration (nAMD) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/neovascular-age-related-macular-degeneration-namd

> 6 upcoming FDA catalysts in neovascular Age-Related Macular Degeneration (nAMD): abp 938 8 mg (AMGN) on Jul to Oct 2027 (topline data readout); abp 938 8 mg (AMGN) on July 2027 (primary completion); 4d-150 ivt (3e10 vg/eye, FDMT) on November 2027 (primary completion); 4d-150 ivt (3e10 vg/eye, FDMT) on Nov 2027 to Feb 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 2026 | [Lucentis® (ranibizumab) primary completion](https://sec-api.dev/pdufa/ranibizumab) | ABBV | Neovascular Age-Related Macular Degeneration (nAMD) | delayed | "NCT04514653 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04514653)) |
| Aug to Nov 2026 | [Lucentis® (ranibizumab) topline data readout](https://sec-api.dev/pdufa/ranibizumab) | ABBV | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT04514653 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04514653)) |
| Jul to Oct 2027 | [Abp 938 8 mg topline data readout](https://sec-api.dev/pdufa/abp-938) | AMGN | Neovascular Age-related Macular Degeneration; nAMD | scheduled | "NCT07614776 (A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614776)) |
| July 2027 | [Abp 938 8 mg primary completion](https://sec-api.dev/pdufa/abp-938) | AMGN | Neovascular Age-related Macular Degeneration; nAMD | scheduled | "NCT07614776 (A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614776)) |
| November 2027 | [4d-150 ivt (3e10 vg/eye) primary completion](https://sec-api.dev/pdufa/4d-150-ivt-3e10-vg-eye) | FDMT | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT07064759 (Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor 4D Molecular Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07064759)) |
| Nov 2027 to Feb 2028 | [4d-150 ivt (3e10 vg/eye) topline data readout](https://sec-api.dev/pdufa/4d-150-ivt-3e10-vg-eye) | FDMT | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT07064759 (Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor 4D Molecular Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07064759)) |
| August 2030 | [Otx-tki primary completion](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT07516132 (Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-01 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07516132)) |
| Aug to Nov 2030 | [Otx-tki topline data readout](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT07516132 (Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-01 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07516132)) |

## Drugs

- [Lucentis® (ranibizumab)](https://sec-api.dev/pdufa/ranibizumab) (ABBV)
- [Abp 938 8 mg](https://sec-api.dev/pdufa/abp-938) (AMGN)
- [4d-150 ivt (3e10 vg/eye)](https://sec-api.dev/pdufa/4d-150-ivt-3e10-vg-eye) (FDMT)
- [Otx-tki](https://sec-api.dev/pdufa/otx-tki) (OCUL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/neovascular-age-related-macular-degeneration-namd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Neovascular Age-Related Macular Degeneration (nAMD) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/neovascular-age-related-macular-degeneration-namd

```bibtex
@misc{secapidev_indications_neovascular_age_related_macular_degeneration_namd_20261116,
  title        = {Neovascular Age-Related Macular Degeneration (nAMD) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/neovascular-age-related-macular-degeneration-namd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_neovascular_age_related_macular_degeneration_namd_20261116","title":"Neovascular Age-Related Macular Degeneration (nAMD) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/neovascular-age-related-macular-degeneration-namd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
